Knopp Biosciences LLC, a drug discovery and development company, announced yesterday that it has commenced phase two dose-ranging clinical trial of oral dexpramipexole in moderate-to-severe eosinophilic asthma.
The company has started recruitment of patients and the first patient has been enrolled. It expects to report top-line data from this trial in the second half of 2020.
This 12-week biomarker study is planned to randomise around 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary result measure of this randomised, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval